EntryPoint Capital’s Maravai LifeSciences MRVI Stock Holding History

EntryPoint Capital’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$594K	Buy	95,186 +9,983	+12%	+$43.1K	0.14%	258
2026 Q1	$241K	Buy	+85,203	New	+$289K	0.07%	565
2025 Q2	–	Sell	-14,423	Closed	-$31.9K	–	735
2025 Q1	$31.9K	Buy	+14,423	New	+$57K	0.01%	648

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

EntryPoint Capital's MRVI Position: Q2 2026 in Review

EntryPoint Capital increased its Maravai LifeSciences (MRVI) stake by 12% in Q2 2026, buying an estimated $43.1K and bringing the position to 95,186 shares worth $594K. The position accounts for 0.14% of the portfolio, ranked #258.

EntryPoint Capital first reported a position in MRVI in Q1 2025 and has held it in 3 quarters since. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

EntryPoint Capital held 95,186 shares of Maravai LifeSciences worth $594K as of Q2 2026.
EntryPoint Capital bought 9,983 Maravai LifeSciences shares in Q2 2026, an estimated $43.1K.
Maravai LifeSciences made up 0.14% of EntryPoint Capital's portfolio in Q2 2026, its #258 holding.
EntryPoint Capital first reported a position in Maravai LifeSciences in Q1 2025 and has held it in 3 quarters since.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.